Infectious Diseases News Round-up

October 2007
PharmaWatch: Monthly Review;Oct2007, Vol. 6 Issue 10, p22
Market Research Report
The article offers news briefs in the pharmaceutical industry. Sinovac Biotech Ltd. has started vaccination of volunteers for a clinical trial of its pandemic avian influenza vaccine. Pharmasset Ltd. has reported preliminary safety and potent antiviral activity with its investigational drug after 14 days of monotherapy in 40 patients chronically infected with hepatitis C virus who had failed prior interferon therapy. MedImmune Inc. has licensed its reverse genetics technology to Novartis AG.


Related Articles

  • COMPANY SPOTLIGHT -- MedImmune.  // PharmaWatch: Monthly Review;Oct2007, Vol. 6 Issue 10, p37 

    The article reports that MedImmune Inc. has licensed its reverse genetics technology to Novartis AG to support the development and construction of new vaccine strains to produce inactivated human seasonal, pre-pandemic and pandemic influenza vaccines. Reverse genetics is a method by which...

  • Infectious Diseases News Round-up.  // PharmaWatch: Monthly Review;Sep2006, Vol. 5 Issue 9, p30 

    The article offers news briefs in the pharmaceutical industry in the U.S. in 2006. A bird flu vaccine developed by GlaxoSmithKline PLC has produced a strong immune response with a low dose of antigen in a 400-patient clinical trial. The U.S. Food and Drugs Administration has informed MedImmune...

  • Pharma: Clinic Roundup.  // BioWorld Today;12/21/2012, Vol. 23 Issue 247, p9 

    The article reports on the results of clinical trials in the biopharmaceutical industry including the primary endpoint missed in Merck and Co. Inc.'s study of Tredaptive and the study by Novartis AG of its ACZ885 compound for systematic juvenile idiopathic arthritis.

  • Novartis Paying $20M Up Front for CMV Candidate.  // Bioworld Week;1/5/2009, Vol. 17 Issue 1, p2 

    The article reports that AlphaVax Inc. has agreed to license rights to its Phase I-stage cytomegalovirus (CMV) vaccine program to Novartis AG in exchange of $20 million up-front payment. According to the term, AlphaVax Inc. will finalize trials for the vaccine candidate while Novartis AG will...

  • COMPANY SPOTLIGHT - MedImmune, Inc.  // PharmaWatch: Biotechnology;Mar2005, Vol. 4 Issue 3, p21 

    The article features biotechnology company MedImmune, and offers information about its corporate history and financial performance. The firm is concentrating in the development and marketing of products in areas such as infectious disease, immune regulation and cancer. It has built a name in...

  • Opinion: Novartis: Menveo is ready to be submitted.  // PharmaWatch: Monthly Review;Jun2008, Vol. 7 Issue 6, p27 

    The article reports on the proven efficacy of meningcoccal vaccine developed by Novartis AG called Menveo. The vaccine is effective in infants and older persons based on trials it had undergone wherein it has been shown to improve on the recent gold standard treatment in certain age groups. The...

  • NexMed Announces Patient Dosing in Phase 3 Program for Anti-Fungal Product.  // Equities;Apr2007, Vol. 55 Issue 2, p124 

    The article reports on the start of patient dosing in the Phase 3 clinical trials for NM100060 anti-fungal treatment of Novartis according to NexMed Inc. which signed a licensing agreement with the pharmaceutical firm. It states that two pivotal, randomized, double-blind and placebo-controlled...

  • Ascent Inks Potential $200M-Plus Deal.  // Bioworld Week;12/15/2008, Vol. 16 Issue 50, p3 

    The article reports on the licensing agreement between Ascent Therapeutics Inc. and Novartis Option Fund in the U.S. The company has entered a licensing option agreement with Novartis, one of the investors in Ascent's $19 million Series A round for the development of Pepducin drug candidates...

  • Novartis: building its antiviral arsenal.  // PharmaWatch: Biotechnology;Jul2006, Vol. 5 Issue 7, p15 

    The article discusses business developments in Novartis AG, a biotechnology company in Europe. The company has signed a licensing deal worth $507 million with Human Genome Sciences Inc. to have rights in co-promoting the hepatitis C drug, Albuferon. This effort is the latest step of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics